In bladder cancer patients the NAT2 high-acetylator phenotypes were WT/WT (46,67%), WT/M1 (25%), and WT/M3 (13.33%) where as M2/M2 (13.33%) was the most common low-acetylator phenotype (Table 5). This evidence concerns the gene NAT2 and urinary bladder carcinoma.